Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial
Authors
Karimi, Y.Ghesquieres, H.
Jurczak, W.
Cheah, C.
Clausen, M.
Lugtenburg, P.
Cunningham, D.
Do, Y. R.
Lewis, D. J.
Gasiorowski, R.
Kim, T. M.
Van der Poel, M.
Poon, M. L. M.
Feldman, T. A.
Linton, Kim M
Sureda, A.
Hutchings, M.
Stirner, M. C.
Sacchi, M.
Thieblemont, C.
Affiliation
University of Michigan Comprehensive Cancer Center, Ann Arbor, MIIssue Date
2023
Metadata
Show full item recordCitation
Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003468.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.7525Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.7525Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.7525